Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate how different surgical tools affect a persons sense of smell after endoscopic endonasal skull base surgery. This type of surgery is commonly used to remove brain tumors involving the pituitary gland and skull base, favored for its minimal invasiveness and faster recovery. However, the olfactory nerve fibers, which are crucial for smell, can be damaged during surgery, potentially lowering quality of life. The study compares two methods for raising the nasoseptal flap during surgery using a scalpel versus using cautery, which generates heat. Participants are randomly assigned to one of these two groups to assess which method better preserves the ability to smell. The trial is prospective and involves careful monitoring of olfactory function before surgery, immediately after, and then 3 to 6 months later. Participants will undergo tests to measure their sense of smell, including the Combined Olfactory Score and Visual Analogue Scale, at multiple time points. They will also complete a questionnaire assessing nasal and sinus symptoms. Researchers will track olfactory changes and recovery over time, aiming to identify the safer surgical method for preserving smell. The study is sponsored by the All India Institute of Medical Sciences, Jodhpur, and will last until 2027.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
Researchers are conducting a multicenter randomized trial to study seizure prevention after traumatic brain injury TBI. The trial compares two anti-epileptic drugs, phenytoin and levetiracetam, against a placebo in patients with early post-traumatic seizures. This study also explores how genetic variations affect seizure occurrence and drug response, aiming to provide high-quality evidence for seizure prophylaxis in TBI patients. Participants are randomly assigned to one of three groups phenytoin, levetiracetam, or placebo. Phenytoin is given initially as an intravenous loading dose followed by maintenance doses for one week, switching to oral extended-release tablets when possible. Levetiracetam is administered intravenously twice daily, then switched to oral extended-release tablets for one week. The placebo group receives matching saline infusions and placebo tablets for the same duration. Genetic testing using real-time PCR will evaluate drug polymorphisms. During the trial, participants are monitored for seizures within seven days after injury, along with changes in neurological status using Glasgow Coma Scale and Glasgow Outcome Scale at discharge, 6 months, and 1 year. Researchers will assess seizure incidence, drug safety, cost-effectiveness, and the impact of genetic factors. The total study duration includes follow-ups up to one year to evaluate clinical and functional outcomes.
Actively Recruiting
Researchers are investigating the effects of pre-operative mouthwash and varying oxygen levels during surgery on the rates of pneumonia and surgical site infections in patients undergoing major abdominal surgery. This trial focuses on patients in low and middle-income countries, where postoperative complications are more common and often more severe. The study aims to find ways to reduce these serious complications, which can cause pain, disability, and increased healthcare costs. Participants will be randomly assigned to one of four groups pre-operative chlorhexidine mouthwash combined with high oxygen levels 80-100% FiO2, no mouthwash with high oxygen levels, mouthwash with low oxygen levels 21-30% FiO2, or no mouthwash with low oxygen levels. Treatments are given around the time of surgery, with oxygen delivered during the operation and mouthwash used before surgery. The study includes an internal pilot phase lasting six months to check recruitment and compliance, followed by a larger trial aiming to enroll nearly 13,000 participants. During the study, researchers will monitor participants for up to 30 days after surgery, assessing rates of pneumonia and surgical site infections using CDC definitions. They will also track other outcomes like mortality, repeat surgeries, hospital stay length, return to normal activities, critical care admissions, and healthcare resource use. Follow-up includes evaluating patient recovery and safety, with all data collected to understand how these interventions impact surgical outcomes in these settings.
Actively Recruiting
Researchers are studying oral squamous cell carcinoma, focusing on patients with advanced nodal disease N2-N3 who are operable and present biologically aggressive tumors. The study aims to evaluate whether adding induction chemotherapy before surgery improves 2-year disease-free survival compared to upfront surgery alone. This phase 3, open-label, multi-center randomized controlled trial addresses previous trial limitations by selecting a more homogenous patient group likely to benefit from chemotherapy. Secondary goals include assessing overall survival, treatment response, compliance, toxicity, postoperative complications, quality of life, and tumor biobanking for future research. The study compares two treatment approaches. The standard arm involves surgery wide local excision with comprehensive neck dissection followed by adjuvant radiotherapy with or without concurrent chemotherapy. The experimental arm adds two cycles of induction chemotherapy using TPF or TPX regimens before surgery and similar adjuvant treatment. Patients will receive standard care according to current guidelines, with surgery timed after assessing chemotherapy response. Participants aged 18 to 75 with confirmed operable oral squamous cell carcinoma and advanced nodal involvement will be followed for up to five years. Researchers will monitor disease-free survival at two years as the primary outcome, alongside overall survival, treatment completion, toxicity, quality of life assessments over multiple timepoints, and surgical morbidity. Tumor and blood samples will be collected for biobanking. Safety and quality of life will be tracked regularly, including early and late radiotherapy-related toxicities and financial impact questionnaires.
Actively Recruiting
Researchers are studying the effects of a yoga-based cardiac rehabilitation program compared to an educational package for patients recovering from heart failure. The goal is to see if yoga classes can effectively support heart health and improve recovery compared to health education. This randomized controlled clinical trial focuses on patients with heart failure and reduced ejection fraction classified as NYHA class II or III. Participants are divided into two groups one receives a yoga-based rehabilitation program called Yoga-CaRe, which includes 20 sessions over three months along with long-term care and follow-up. The other group receives enhanced standard care through three health education sessions spread over the same period. Both interventions aim to improve heart health and quality of life. During the study, participants attend scheduled sessions and are monitored over time. Researchers assess major adverse cardiovascular events over a median follow-up of one year and evaluate heart failure-specific quality of life and physical function, such as the six-minute walk test, at three months. Additional measures include general quality of life, self-rated health, tobacco cessation, frailty, caregiver well-being, and healthcare costs. This study is led by the Centre for Chronic Disease Control in India and follows participants for up to one year.